Effect of fasting ramadan in diabetes control status-application of extensive diabetes education, serum creatinine with hba1c statistical anova and regression models to prevent hypoglycemia

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 3, 2013, Pages 233-251

  Aziz, Kamran M A ^a  

^a ASEER CENTRAL HOSPITAL   (Saudi Arabia)

Author keywords

ANOVA; CRD CKD; Creatinine; Diabetes; Hypoglycemia; Insulin; OHA; Ramadan; Regression; SMBG

Indexed keywords

BIPHASIC INSULIN; CREATININE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONFUSION; CREATININE BLOOD LEVEL; CULTURAL ANTHROPOLOGY; DIABETES CONTROL; DIABETES EDUCATION; DIABETES MELLITUS; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; EXERCISE; FAINTNESS; FEMALE; FIELD WORK; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MOSLEM; PATIENT EDUCATION; PRIORITY JOURNAL; RETINOPATHY; SWEATING; TREMOR;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; CREATININE; DATA COLLECTION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EXERCISE; FASTING; FEMALE; HEALTH EDUCATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISLAM; MALE; PATENTS AS TOPIC; PATIENT EDUCATION AS TOPIC; REGRESSION ANALYSIS; SOCIOECONOMIC FACTORS;

EID: 84888093363     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/18715303113139990010     Document Type: Article

References (278)

1. Ahmed A, Mustapha A, Ahmed MS, Yusoff MZM. Analyzing the Principles of Islamic Jurisprudence for a normative framework in multi-agent systems. Int J Quranic Res 2011; 1(1):51-72.
2. Sakr AH. Fasting in Islam. J Am Diet Assoc 1975; 67:17-21.
3. Rashed AH. The fast of Ramadan. Br Med J 1992; 304:521-2.
4. Miller T. Mapping the global Muslim population. A Report on the Size and Distribution of the World's Muslim Population, Pew Research Center, Washington, D.C., 2009. Available at http://.pewforum.org/.../muslimpopulation/muslimpopulation.pdf. (Accessed on: November 1, 2012).
5. Kettani H. 2010 world Muslim population. Proceedings of the 8th Hawaii International Conference on Arts and Humanities, Honolulu, Hawaii, January 2010. Available at http://.pupr.edu/hkettani/papers/HICAH2010.pdf. (Accessed on: November 1, 2012).
6. Kettani H. Muslim Population in Europe: 1950-2020. Int J Environ Sci Develop 2010; 1: 154-64.
7. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993; 16:157-77.
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53.
9. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
10. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
11. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
12. Writing team for the Diabetes Control and Complications Trial/Epidemiology for Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290:2159-67.
13. Al-Arouj M, Bouguerra R, Buce J, Hafez S, Hassanein M, Ibrahim MA, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005; 28: 2305-11.
14. Salti I, Benard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27:2306-11.
15. Khalil HM. Effect of Ramadan fasting on arterial blood pressure. TMJ 2004; 10(1): 12-6.
16. Maislos M, Abu-Rabiah Y, Zuili I, Shaney S. Improved diabetes control after prolonged fasting-the Ramadan model. Pract Diabetes Int 2001; 18:149-51.
17. Iraki L, Bogdam AF, Abkari AL. Ramadan diet restrictions modify the circadian time structure in human. J Clin Endocrinol 1997; 82: 1261-73.
18. Ayabak, MA. Effect of RF on platelet aggregation in healthy male subjects. Eur J Appl Physiol 1996; 73:552-6.
19. Marbut MM, Al-Najjar HSM, Abdul-Rahman MA. Effect of Ramadan fasting on some physiological parameters. Tikrit Med J 2005; 11(2): 6-8.
20. Porksen N, Munn S, Steers J, Vore S, Veldhuis J, Butler P. Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting. Am J Physiol 1995; 269: E478-88.
21. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988; 31: 355-60.
22. Van Haeften T, Pimenta W, Mitrakou A, Korytkowski M, Jenssen T, Yki-Järvinen H, et al. Relative contributions of cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000; 49: 1318-25.
23. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulate both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
24. Salehi M, Aulinger BA, D' Alessio DA. Targeting beta-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins. Endocr Rev 2008; 29: 367-79.
25. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002; 45: 1263-73.
26. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001; 15: 1559-70.
27. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988; 9: 122-34.
28. Hoffmann, J.A. GLP-1 formulations. US6358924 (2002).
29. Sugita, K., Kasahara, S., Ebinuma, H., Takaiwa, F., Jomori, T., Hayashi, Y. GLP-1 derivative. US7847063 (2010).
30. Perfetti, R. Human glucose dependent insulin-secreting cell line. US6642003 (2003)
31. World Health Organization (WHO). Diabetes Mellitus: Report of a Study Group. Technical Report Series 727. Geneva: WHO, 1985.
32. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
33. Fryburg, D.A., Gibbs, E.M., Koppiker, N.P. Treatment of diabetes mellitus. US6683080 (2004).
34. Piper, B.A. Method for treating diabetes. US7598262 (2009).
35. Larsson H, Berglund G, Ahren B. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 1995; 80:1778-82.
36. O' Meara N, Sturis J, VanCouter E, Polonsky K. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 1993; 92: 262-71.
37. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-9.
38. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-83.
39. WHO Expert Committee on Diabetes Mellitus. Education. Second report. Technical report series 646. Geneva: World Health Organization, 1980:58.
40. Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P, et al. National standards for diabetes self-management education. Diabetes Care 2000; 23:682-9.
41. Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, et al. Longitudinal study of new and prevalent use of selfmonitoring of blood glucose. Diabetes Care 2006; 29:1757-63.
42. Boutati EI, Raptis SA. Self-monitoring of blood glucose as part of the integral care of type 2 Diabetes. Diabetes Care 2009; 32 (Suppl. 2):S205-S10.
43. Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Cavaliere D, Nardo BD, et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 Diabetic patients. An urgent need for better educational strategies. Diabetes Care 2001; 24:1870-7.
44. Welschen LMC, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al. Self-monitoring of blood glucose in patients with type 2 Diabetes who are not using insulin. A systematic review. Diabetes Care 2005; 28 (6): 1510-7.
45. Murata, G. System and methods for estimating HbA1c, treatment response, and hypoglycemia risk using self-monitoring of blood glucose data. US253840 (2012).
46. Laufer, M., Burnett, D. Glucose monitoring device and method. US7783332 (2010).
47. Ofili, E., Pemu, P., Quarshie, A., Johnson, P., Linn, L. Ali, J., Kaur, D. System and method for chronic illness care. US8234131 (2012).
48. Cahir, N. Diagnostic device. US106373 (2006).
49. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003; 26 (Suppl 1):S51-61.
50. Clark, R.M. Diabetic diet plan aid and method. US4976622 (1990).
51. Brenkus, J., Gorman, K. Diet method and apparatus. US6296488 (2001).
52. Koenig, D. Diabetic diet management system. US15723 (2002).
53. Chait, A., Hatton, D., Haynes, B.R., Khoo, C.S., Kris-Etherton, P., Macnair, D.R.C., McCarron, D., Metz, J., Oparil, S., Pi-Sunyer, X., Resnick, L., Stern, J.S., Ziegler, P.J. Method for determining diet program effectiveness. US5639471 (1997).
54. Mansi KMS. Study the effects of ramadan fasting on the serum glucose and lipid profile among healthy Jordanian students. Am J Appl Sci 2007; 4 (8): 565-9.
55. Faris MAE, Hussein RN, Al-Kurd RA, Al-Fararjeh MA, Bustanji YK, Mohammad MK. Impact of Ramadan intermittent fasting on oxidative stress measured by urinary 15-F2t-isoprostane. J Nutr Metab 2012; 2012: 802924.
56. Bahammam A. Effect of fasting during Ramadan on sleep architecture, daytime sleepiness and sleep pattern. Sleep Biol Rhythms 2004; 2: 135-43.
57. El-Magd KMA, Mirakhur A, Patel P, El-Matty ANA, Al-Ghafri D. Type 2 and its characteristics during Ramadan in Dhahira region, Oman. Oman Med J 2007; 22 (3):18-23.
58. Rahman O, Islam R. Association between Fasting of Ramadan and Risk Factors of Diabetes: A Study from Rajshahi city in Bangladesh. Adv J Food Sci Technol 2011; 3(5): 360-5.
59. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea, and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocrine Res 2004; 30 (2): 169-77.
60. Ait Saada D, Selselet AG, Belkacemi L, Ait chabane O, Bekada AMA, Kati D, et al. Effect of Ramadan fasting on glucose, glycosylated haemoglobin, insulin, lipids and proteinous concentrations in women with non-insulin dependent diabetes mellitus. African J Biotechnol 2010; 9 (1): 87-94.
61. Rohban T. The efficacy and safety of glimepiride in the management of Type 2 Diabetes in Muslim patients during Ramadan. Diabetes Care 2005; 28: 421.
62. Nematy M, Namaghi MA, Rashed MM, Mozhdehifard M, Akhlaghi S, Sabery M, et al. Effects of Ramadan fasting on cardiovascular risk factors: A prospective observational study. BMC Nutr J 2012; 11:69.
63. Wei CT. Diabetes mellitus and fasting during Ramadan. Singapore Fam Physician 2011; 37(2): 52-9.
64. Asgary S, Aghaei F, Naderi GA, Kelishadi R, Gharipour M, Azali S. Effects of Ramadan fasting on lipid peroxidation, serum lipoproteins and fasting blood sugar. Med J Islamic Acad Sci 2000; 13(1): 35-8.
65. Belkhadir J, Ghomari HE, Klöcker N, Mikou A, Nasciri M, Sabri M. Muslims with non-insulin dependent diabetes fasting during Ramadan: Treatment with glibenclamide. BMJ 1993; 307(6899):292-5.
66. Zerguini Y, Dvorak J, Leiper JB, Bartagi Z, Kirkendall DT, Al-Riyami M. Influence of Ramadan fasting on physiological and performance variables in football players: Summary of the F-MARC 2006 Ramadan fasting study. J Sports Sci 2008; 26 (Suppl 3):S3-6.
67. Meckel Y, Ismaeel A, Eliakim, A. The effect of the Ramadan fast on physical performance and dietary habits in adolescent soccer players. Eur J Appl Physiol 2008; 102(6):651-7.
68. Shirreffs SM, Maughan, RJ. Water and salt balance in young male football players in training during the holy month of Ramadan. J Sports Sci 2008; 26(suppl 3): S47-S54.
69. Zerguini Y, Kirkendall D, Junge A, Dvorak J. Impact of Ramadan on physical performance in professional soccer players. Br J Sports Med 2007; 41:398-400.
70. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Nauck M, Matthews D, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203.
71. Aziz KM. Management of type-1 and type-2 diabetes by insulin injections in diabetology clinics-a scientific research review. Recent Pat Endocr Metab Immune Drug Discov 2012; 6(2):148-70.
72. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: National clinical guideline management in primary and secondary care (update). London: Royal College of Physicians, 2008.
73. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-3.
74. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22:1258-61.
75. Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S, et al. Use of premixed insulin among the elderly. Diabetes Care 1992; 15:1628-30.
76. Chen JW, Lauritzen T, Bojesen A, Christiansen JS. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab 2006; 8(6):682-9.
77. Farcasiu E, Ivanyi T, Pastewka BM, Birkus Z, Csog J, Kowalska I, et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type-2 Diabetes Mellitus: A randomized, 16-week, open-label study. Clin Ther 2011; 33:11.
78. Akram J, De Verga V. Insulin Lispro (Lys (B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. Diabet Med 1999; 16:861-6.
79. Skyler JS. Insulin therapy in type 1 diabetes mellitus. In current therapy of Diabetes Mellitus. De Fronzo RA, Ed. St. Louis, MO, Mosby, 1998; 36-49.
80. Zinman B. The physiologic replacement of insulin. N Engl J Med 1989; 321: 363-70.
81. DeWitt DE, Hirsch IB. Outpatient insulin treatment in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289:2254-64.
82. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002: 24: 629-38.
83. Dall V. Preclinical safety pharmacology studies on the rapid-acting insulin analogue, insulin aspart. Artzneim Forsch Drug Res 1999; 49: 463-70.
84. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes mellitus: Clinical applications. JAMA 2003; 289:2265-9.
85. Hirsch IB, Farkas-Hirsch R, Skyler JS. Intensive insulin therapy for treatment of type 1 diabetes. Diabetes Care 1990; 13:1265-83.
86. Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycemia and frequency hypoglycemia in IDDM patients on insulin-analogue treatment. Diabetes 1997; 46:265-70.
87. NICE. (National Institute of Clinical Excellence). Guidance on the use of long-acting insulin analogs for the treatment of diabetesinsulin glargine. Technology Appraisal Guidance No 53. 2002. Available at http://guidance.nice.org.uk/TA53/guidance/pdf/English (Accessed on: December 6, 2012).
88. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogs (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004: 47: 622-9.
89. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999: New approaches to insulin treatment and glucose monitoring. Diabetes Care 1999; 22: 2078-82.
90. Deeb LC, Holcombe JH, Brunelle R, Zalani S, Brink S, Jenner M, et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001: 108: 1175-9.
91. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002: 24: 629-38.
92. Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin N Am 2005; 34: 77-98.
93. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(9): 550-4.
94. UKPDSG. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21(1): 87-92.
95. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131(3): 182-8.
96. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.
97. Riddle MC. Combined therapy with insulin plus oral agents: Is there any advantage? An argument in favor. Diabetes Care 2008; 31 (Suppl 2):S130.
98. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108(6A): 15S-22S.
99. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-65.
100. Hoffmann, J.A. GLP-1 formulations. US6358924 (2002).
101. Sugita, K., Kasahara, S., Ebinuma, H., Takaiwa, F., Jomori, T., Hayashi, Y. GLP-1 derivative. US7847063 (2010).
102. Irl BH, Richard MB, Christopher GP, Eugene W, John BB. A real world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23(2):78-86.
103. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. JAMA 1997; 278:1663-9.
104. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-75.
105. Riddle MC. Timely initiation of basal insulin. Am J Med 2004; 116(3A): 3S-9S.
106. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:1426-33.
107. Riddle MC, Schneider J. The Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998; 21: 1052-7.
108. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49: 442-51.
109. Riddle MC, Rosenstock J, Gerich J. The insulin glargine 4002 study investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6.
110. Kennedy L, Herman WH, Strange P, Harris A. The GOAL A1c Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurements of HbA1c on glycemic control in type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at point of care (GOAL A1C) trial. Diabetes Care 2006; 29: 1-8.
111. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins P-E. Comparison of bedtime NPH or pre-prandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18: 1183-6.
112. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-9.
113. Raccha D, Bretzel RG, Owens D, Riddle MC. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev 2007; 23: 257-64.
114. M-Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357(17):1716-30.
115. Del Prato1 S, Nicolucci A, Vespasiani G. Optimizing basal plus insulin therapy in type 2 diabetes by telecare assistance for self monitoring of blood glucose-the ELEONOR study. Diabetologia 2008; 51(Suppl1): S1-S588.
116. Lankisch MR, Ferlinzet KC, Leahy JL, Scherbaum WA. Orals plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10(12):1178-85.
117. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clini Pharmacokinet 2002; 41(13):1043-57.
118. Roach P, Yu L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22:1258-61.
119. Jacobsen LV, Sogaard B, Ris A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamineretarded insulin aspart. Eur J Clin Pharmacol 2000; 56(5):399-403.
120. Raskin P, Allen E, Hollander P. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5.
121. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type 2 diabetics. Metabolic effects during a 6 month outpatient trial. Diabetes Care 1993; 161(1): 21-31.
122. Kuddlacek S, Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary failure to sulfonylureas. A five year follow-up study. Horm Metab Res 1992; 24: 478.
123. Bashir MI, Pathan MF, Ahmad J, Khan AK, Ishtiaq O, Sheikh A, et al. Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. Indian J Endocrinol Metab 2012; 16(4): 503-7.
124. Azad K, Mohsin F, Zargar AH, Zabeen B, Ahmad J, Tayyeb S, et al. Fasting guidelines for diabetic children and adolescents. Indian J Endocrinol Metab 2012; 16(4):516-8.
125. Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia 2006; 61(1): 28-35.
126. Kassem HS, Zantout MS, Azar ST. Insulin therapy during Ramadan fast for type 1 diabetes patients. J Endocrinol Invest 2005; 28(9): 802-5.
127. Benaji B, Mounib N, Roky R, Aadil N, Houti IE, Moussamih S, et al. Diabetes and Ramadan: Review of the literature. Diabetes Res Clin Pract 2006; 73(2):117-25.
128. Zargar A, Basit A, Mahtab H. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan. J Indian Med Assoc 2005; 103(8): 444-6.
129. Hassanein M. Diabetes and Ramadan: How to achieve a safer fast for Muslims with diabetes. Br J Diabetes Vascular Disease 2010; 10: 246.
130. Al-Maatouq MA. Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. Diabetes, Met Syndr Obes Target Ther 2012; 5: 109-19.
131. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-42.
132. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64:1339-58.
133. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabet Res Clin Pract 2002; 58: 45-53.
134. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-33.
135. Ahmed MH, Abdu T. Diabetes and Ramadan: An update on use of glycemic therapies during fasting. Ann Saudi Med 2011; 31(4): 402-6.
136. Suliman M, Abdu T, Elhadd T, Ibrahim S, Ahmed MH, Malik R. Diabetes and fasting in Ramadan: Can we provide evidence-based advice to patients? Sudan Med J 2010; 46(1): 4-14.
137. Zargar AH, Siraj M, Jawa AA, Hasan M, Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract 2010; 64: 1090-4.
138. Rohban T. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005; 28: 421-2.
139. Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK, et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59: 137-43.
140. Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care 2004; 27: 1209-10.
141. Kobeissy A, Zantout MS, Azar ST. Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan. Clin Ther 2008; 30: 1408-15.
142. Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al AM, Akram J, et al. Treatment of type 1 diabetes with insulin lispro during Ramadan. Diabetes Metab 2001; 27: 482-6.
143. Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of 28 Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract 2010; 64: 1095-9.
144. Vasan S, Thomas N, Bharani MA, Abraham S, Job V, John B, et al. A double blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Intl J Diabetes Dev Countries 2006; 26: 70-6.
145. Sulimani RA. Management of type 2 diabetes with oral hypoglycaemics during Ramadan. Pract Diabetes Int 1998; 15(1): S9.
146. Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: Results of the VECTOR study. Curr Med Res Opin 2011; 27: 1367-74.
147. Crye PE. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005; 28: 1245-9.
148. NATCOM Hospital Information System (NATCOM HIS), National Computer System Co, Ltd. http://natcom.com.sa/healthcare and http://natcom.com.sa/clients (Accessed on: November 17, 2011).
149. Healy MJR. Statistics from the inside. 11. Data transformations. Arch Dis Child 1993; 68: 260-4.
150. Lang TA, Secic M. How to report statistics in medicine. Philadelphia, PA: American College of Physicians, 1997; 48.
151. Chinn S. Scale, parametric methods, and transformations. Thorax 1991; 46: 536-538.
152. Bland JM, Altman DG. Transforming data. BMJ 1996; 312: 770.
153. Altman DG, Bland JM. Presentation of numerical data. BMJ 1996; 312: 572.
154. Stevens J. Applied multivariate statistics for the social sciences (3rd edition). Mahwah, NJ: Lawrence Erlbaum Associates, 1996; 237-260.
155. Norman GR, Streiner DL. One-way ANOVA. In: Biostatistics. The bare essentials. Missouri, USA: Mosby, 1994; 64-72.
156. Altman DG, Bland JM. Comparing several groups using analysis of variance. BMJ 1996; 312: 1472-3.
157. Norman GR, Streiner DL. Biostatistics. The bare essentials. Missouri, USA: Mosby Year Book Inc, 1994: 168.
158. Markowski, Carol A, Markowski EP. Conditions for the effectiveness of a preliminary test of variance. Am Stat 1990; 44 (4): 322-6.
159. Sawilowsky S, Fermat, S, Behrens-Fisher E. The probable difference between two means when 1 2 2 2. J Mod App Stat Meth 2002; 1(2): 461-72.
160. Simpson J, Berry G. Simple regression and correlation. In: Handbook of public health methods, Kerr C, Taylor R, Heard G (editors). Roseville, Australia: McGraw-Hill Companies Inc, 1998: 288-95.
161. Peat JK, Mellis CM, Williams K, Xuan W. Confounders and effect modifiers. In: Health science research. A handbook of quantitative methods. Crows Nest: Allen and Unwin 2001; 90-104.
162. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. Pacific Grove, California: Duxbury Press, 1998; 237-45.
163. Kachigan, SK. Multivariate statistical analysis (2nd edition). New York: Radius Press, 1991; 172-4.
164. Altman DG. Reference intervals. In: Practical statistics for medical research, London 1991; 419-23.
165. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19:589-601.
166. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. Pacific Grove, California: Duxbury Press, 1998; 237-45.
167. Bland M. An introduction to medical statistics (2nd edition). Oxford, UK: Oxford University Press, 1996.
168. Fereidoun A. Research in Islamic fasting and health. Ann Saudi Med 2002; 22: 186-91.
169. Frost G, Pirani S. Meal frequency and nutritional intake during Ramadan: A pilot study. Hum Nutr Appl Nutr 1987; 41: 47-50.
170. Bogdan A, Bouchareb B, Touitou Y. Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans? Life Sci 2001; 68: 1607-15.
171. Rocky R, Iraki L, HajKhlifa R, Ghazal NL, Hakkou F. Daytime alertness, mood, psychomotor performance and oral temperature during Ramadan intermittent fasting. Ann Nutr Metab 2000; 44: 101-7.
172. Rocky R, Chapotot F, Taoudi M, Benaji B, Hakkou F, El Khalifi H, Buguet A. Daytime sleepiness during Ramadan intermittent fasting: Polysomnographic and quantitative waking EEG study. J Sleep Res 2003; 12: 95-101.
173. Al-Hadramy MS, Hawaii TH, Abdelwahab SM. Altered cortisol levels in relation to Ramadan. Eur J Clin Nutr 1988; 42: 359-62.
174. Sliman NA, Ajlouni KS, Khatib FA. Effect of fasting Ramadan on some blood hormones in healthy Muslim males. Mu'tah J Res Studies 1993; 8: 91-109.
175. Chowdhury TA, Hussain HA, Hayes M. An educational class on diabetes self-management during Ramadan. Pract Diabetes Int 2003; 20(8):306-7.
176. Wilson, D.E., Hart, J.K. Health care education systems. US189133 (2008).
177. Mulcahy, K., Maryniuk, M., Peeples, M., Tomky, D., Weaver, T., Yarborough, P. Method for improving patient chronic disease education. US268412 (2008).
178. Brown, S. Diabetes management system. US7869852 (2011).
179. Beaton, C. Continuing patient education program. US202363 (2011).
180. Uysal AR, Erdogan MF, Sahin G Kamel N, Erdogan G. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan. Diabetes Care 1998; 21:2033-4.
181. Laajam MA. Ramadan fasting and non-insulin-dependent diabetes: Effect on metabolic control. East Afr Med J 1990; 67:732-6.
182. Pinar R. Management of people with diabetes during Ramada. Br J Nur 2002; 11:1300-3.
183. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010; 103: 139-47.
184. Aadil N, Houti IE, Moussamih S. Drug intake during Ramadan. BMJ 2004 2; 329(7469):778-82.
185. Beltaifa L, Bouguerra R, Ben Slama C, Jabrane H, El-Khadhi A, Ben Rayana MC, et al. Food intake, and anthropometrical and biological parameters in adult Tunisians during fasting at Ramadan. East Mediterr Health J 2002; (4-5):603-11.
186. Khatib FA, Shafagoj YA. Metabolic alterations as a result of Ramadan fasting in non-insulin-dependent diabetes mellitus patients in relation to food intake. Saudi Med J 2004; 25(12):1858-63.
187. Bouguerra R, Jabrane J, Maâtki C, Ben Salem L, Hamzaoui J, El Kadhi A, et al. Ramadan fasting in type 2 diabetes mellitus. Ann Endocrinol 2006; 67(1):54-9.
188. Ahmadani MY, Riaz M, Fawwad A, Hydrie MZ, Hakeem R, Basit, A. Glycaemic trend during Ramadan in fasting diabetic subjects: A study from Pakistan. Pak J Biol Sci 2008; 11(16):2044-7.
189. Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, et al. Engel SS; 2010 Ramadan Study Group. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial. Int J Clin Pract 2011; 65(11):1132-40.
190. Aravind SR, Al Tayeb K, Ismail SB, Shehadeh N, Kaddaha G, Liu R, et al. 2009 Ramadan Study Group. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: A five-country country observational study. Curr Med Res Opin 2011; 27: 1237-42.
191. Aravind SR, Ismail SB, Balamurugan R, Davies MJ, Girman CJ, Katzeff HL, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: A randomized, pragmatic study. Curr Med Res Opin 2012; 28(8):1289-96.
192. Cesur M, Corapcioglu D, Gursoy A, Gonen S, Ozduman M, Emral R, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007; 75: 141-7.
193. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea, and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004; 30: 169-77.
194. Bakiner O, Ertorer ME, Bozkirli E, Tutuncu N.B, Demirag NG. Repaglinide plus single-dose insulin glargine: A safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan Acta Diabetol 2009; 46(1):63-5.
195. Burden M. Culturally sensitive care: Managing diabetes during Ramadan. Br J Community Nurs 2001; 6(11):581-5.
196. Loke SC, Rahim KF, Kanesvaran R, Wong TW. A prospective cohort study on the effect of various risk factors on hypoglycaemia in diabetics who fast during Ramadan. Med J Malaysia 2010; 65(1):3-6.
197. Berman, H.L., Roe, J.N., Blair, R.N. Glucose measurement utilizing noninvasive assessment methods. US7039447 (2006).
198. Robertshaw, M. Prediction of creatinine clearance from plasma creatinine: Comparison of five formulae. Br J Clin Pharmac 1989; 28: 275-80.
199. Gowans EM, Fraser CG. Biological variation of serum and urine creatinine and creatinine clearance. Ann Clin Biochem 1988; 25 (Pt 3):259-63.
200. Cockcroft DW, Gault MH. Prediction of creatinine clearance from the serum creatinine. Nephron 1976; 16(1):31-41.
201. Rosano TG, Brown HH. Analytical and biological variability of serum creantinine and creatinine clearance. Clinl Chem 1982; 28: 2330-31.
202. Rossing P, Rossing K, Gæde P, Pedersen O, Parving HH. Monitoring kidney function in type 2 diabetic patients with incipient and overt nephropathy. Diabetes Care 2006; 29: 1024-30.
203. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.
204. Levey AS, Coresh J, Greene T; for the Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomeurlar filtration rate. Ann Intern Med 2006; 145: 247-54.
205. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007; 18: 2749-57.
206. Basker V, Venugopal H, Holland MR, Singh BM. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population. Diabet Med 2006; 23: 1057-60.
207. Chudleigh RA, Dunseath G, Evans W, Harvey JN, Evans P, Ollerton R, et al. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 2007; 30: 300-5.
208. Kell, M. Method of determining renal clearances. US5602038 (1997).
209. Krolewski, A.S., Warren, J. Method of evaluating a subject for risk or predisposition of reduced renal function over time. US7560244 (2009).
210. Krolewski, A.S., Warren, J. Predictors of renal disease. US20060240437 (2006).
211. Verheijen, J.H., Hanemaaijer J.R., Diamant, M. Method for determining if a subject having type II diabetes has a kidney disorder. US8012709 (2011).
212. Niewezas, M.A., Krolewski, A.S. Methods of diagnosing and predicting renal disease. US20010281758 (2001).
213. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE; NGSP Steering Committee. The national glycohemoglobin standardization program: A five-year progress report. Clin Chem 2001; 47:1985-92.
214. Berg AH, Sacks DB. Haemoglobin A1c analysis in the management of patients with diabetes: From chaos to harmony. J Clin Pathol 2008; 61:983-7.
215. Ravi, N. Managing glycemia status in diabetic patients. US7670794 (2010).
216. Zeuthen, J., Prento, A., Kruse, V. Determination of glycated (glycosylated) hemoglobin in blood. US005206144 (1993).
217. Yonehara, S., Inamura, N. Method of measuring HBA1C. US008008085 (2011).
218. Thukral, A., Weinert, S., Inamura, N. Method, system, and computer program product for providing both estimated true mean blood glucose value and estimated glycated hemoglobin (HBA1C) value from structured spot measurements of blood glucose. US0330598 (2010).
219. Azizi F. Islamic fasting and health. Ann Nutr Metab 2010; 56:273-82.
220. Toda M, Morimoto K: Effects of Ramadan fasting on the health of Muslims. Nippon Eiseigaku Zasshi 2000; 54(4):592-6.
221. Ziaee V, Razaei M, Ahmadinejad Z, Shaikh H, Yousefi R, Yarmohammadi L, et al. The changes of metabolic profile and weight during Ramadan fasting. Singapore Med J 2006; 47:409-14.
222. Salehi M, Neghab M. Effects of fasting and a medium calorie balanced diet during the holy month Ramadan on weight, BMI and some blood parameters of overweight males. Pak J Biol Sci 2007; 15: 10(6):968-71.
223. Yucel A, Degirmenci B, Acar M, Albayrak R, Haktanir A. The effect of fasting month of Ramadan on the abdominal fat distribution: Assessment by computed tomography. J Exp Med 2004; 204(3):179-87.
224. El Ati J, Beji C, Danguir J. Increased fat oxidation during Ramadan fasting in healthy women: An adaptative mechanism for bodyweight maintenance. Am J Clin Nutr 1995; 62(2):302-7.
225. Roky R, Houti I, Moussamih S, Qotbi S, Aadil N. Physiological and chronobiological changes during Ramadan intermittent fasting. A Ann Nutr Metab 2004; 48(4):296-303.
226. Lamri-Senhadji MY, El Kebir B, Belleville J, Bouchenak M. Assessment of dietary consumption and time-course of changes in serum lipids and lipoproteins before, during and after Ramadan in young Algerian adults. Singapore Med J 2009; 50(3):288-94.
227. Leiper JB, Molla AM. Effects on health of fluid restriction during fasting in Ramadan. Eur J Clin Nutr 2003; 57 (Suppl 2): S30-8.
228. Trepanowski JF, Canale RE, Marshall KE, Kabir MM, Bloomer RJ. Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: A summary of available findings. Nutr J 2011; 10:107.
229. Rahman M, Rashid M, Basher S, Sultana S, Nomani MZ. Improved serum HDL cholesterol profile among Bangladeshi male students during Ramadan fasting. East Mediterr Health J 2004; 10(1-2):131-7.
230. Haouari M, Haouari-Oukerro F, Sfaxi A, Ben Rayana MC, Kâabachi N, Mbazâa A. How Ramadan fasting affects caloric consumption, body weight, and circadian evolution of cortisol serum levels in young, healthy male volunteers. Horm Metab Res 2008; 40(8): 575-7.
231. Aksungar FB, Eren A, Ure S, Teskin O, Ates G. Effects of intermittent fasting on serum lipid levels, coagulation status and plasma homocysteine levels. Ann Nutr Metab 2005; 49(2):77-82.
232. Aldouni A, Ghalim N, Saile R, Had N, Benslimane A. Beneficial effect on serum apo AI, apo B and Lp AI levels of Ramadan fasting. Clin Chim Acta 1998; 52: 127-30.
233. Martin B, Mattson MP, Maudsley M. Caloric restriction and intermittent fasting: Two potential diets for successful brain aging. Ageing Res Rev 2006; 5(3):332-53.
234. Varady KA, Hellerstein MK. Alternate-day fasting and chronic disease prevention: A review of human and animal trials. Am J Clin Nutr 2007; 86(1):7-13.
235. Lee KH, Bartsch H, Nair J, Yoo DH, Hong YC, Cho SH, et al. Effect of short-term fasting on urinary excretion of primary lipid peroxidation products and on markers of oxidative DNA damage in healthy women. Carcinogenesis 2006; 27(7):1398-403.
236. El Ati J, Beji C, Danguir J. Increased fat oxidation during Ramadan fasting in healthy women: An adaptative mechanism for bodyweight maintenance. Am J Clin Nutr 1995; 62 (2): 302-7.
237. Mattson MP, Wan R. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. J Nutr Biochem 2005; 16(3):129-37.
238. Hui E, Bravis V, Hassanein M, Hanif W, Malik R, Chowdhury TA, et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010; 340:c3053.
239. Khaled BM, Belbraouet S. Ramadan fasting diet entailed a lipid metabolic disorder among type 2 diabetic obese women. Am J Appl Sciences 2009; 6: 471-7.
240. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan education and awareness in diabetes (READ) program for Muslims with type 2 diabetes who fast during Ramadan. Diabetes Med 2010; 27:327-31.
241. Mojaddidi M, Hassanein M, Malik R. Ramadan and diabetes: Evidence-based guidelines. Prescriber 2006:38-41.
242. Al-Hourani HM, Atoum MF. Body composition, nutrient intake and physical activity patterns in young women during Ramadan. Singapore Med J 2007; 48(10):906-10.
243. Mcpeak, P., Cheruvanky, R., Cherukuri, R.S. Supportive therapy for diabetes, hyperglycemia and hypoglycemia. US6303586 (2001).
244. Zapp, G. Processing and cooking of food with a low glycemic impact for the nutrition of diabetics, obese and for weight reducing diets. US151076 (2011).
245. Brown, S.J. Method and system for improving adherence with a diet program or other medical regimen. US7297109 (2007)
246. Mcpeak, P., Cheruvanky, R., Cherukuri, R.S. A method for treating diabetes, hyperglycemia and hypoglycemia. WO1999010002 (1999).
247. Arana, P.R. Diet planner and method. US2005048454 (2005).
248. Beaumont, K., Young A.A. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions. US5321008 (1994).
249. Khogeer Y, Suliman MI, Al-Fayez SF. Ramadan fasting and diabetes safety and state of control. Ann Saudi Med J 1987; 7 (Suppl):6-7.
250. Laayam MA. Ramadaan fasting and non-insulin dependent diabetes: Effect on clinical control. East Ajr Med J 1990; 7:732-6.
251. Mafauzy M, Mohammad WB, Anum MY, Zulkifli A, Ruhani AH. A study of the fasting diabetic patients during the month of Ramadan. Med J Malaysia 1990; 45:14-7.
252. Maislos M, Khamaysi N, Assali A, Abou-Rabiah Y, Zvili I, Shany S. Marked increase in plasma high density-lipoprotein cholesterol after prolonged fasting during Ramadan. Am J Clin Nutr 1993; 57 (5): 640-2.
253. Wei CT. Diabetes mellitus and fasting during Ramadan. Singapore Fam Phy 2011; 13 (2): 52-9.
254. Omar MAK. Fasting and some common medical illnesses in fasting and the patient. Some Guidelines. Durban, South Africa, Islamic Medical Association 1984; 17-18
255. Faris ME, Hussein RN, Al-Kurd RA, Al-Fararjeh MA, Bustanji YK, Mohammad MK. Impact of Ramadan intermittent fasting on oxidative stress measured by urinary 15-F2t-isoprostane. J Nutr Metab 2012; 2012: 802924.
256. Beshyah SA. Fasting during the month of Ramadan for people with diabetes: Medicine and Fiqh united at last. Ibnosina J Med Biomed Sci 2009; 1:58-60.
257. Akbani MF, Saleem M, Gadit WU, Ahmed M, Basit A, Malik RA. Fasting and feasting safely during Ramadan in the patient with diabetes. Pract Diabetes Int 2005; 22:100-4.
258. Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections. Clin Ther 2007; 29 (Suppl D): S135-44.
259. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulindependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125: 177-88.
260. De Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, Den Boer NC, Grose WF, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: Two-year follow-up of a randomized, prospective trial. Diabet Med 1989: 6: 766-71.
261. Garg S, Zisser HC, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, realtime continuous glucose sensor. Diabetes Care 2006; 29:44-50.
262. Leiva AD, Hernando ME. Telemedical artificial pancreas. Diabetes Care 2009; 3: (Suppl 2): S211-6.
263. Christofer, T., Pantelis, G., Pau Herrero, V., Calvin, S. Insulin pump. US20130041343 (2013).
264. Goodnow, T.T., Blomquist, M.L., Johnson, J.G. Glucose measuring module and insulin pump combination. US7850674 (2010).
265. Blomquist, M. Insulin pump based expert system. US8221345 (2012).
266. Bernini, N., Galley, P.J., Lindegger, S., Sigrist, R., Wagner, R.S., Wilson, R.W. Insulin pump and methods for operating the insulin pump. US20130041342 (2013).
267. Blomquist, M. Expert system for insulin pump therapy. US7751907 (2010).
268. Haar, H., Meacham, G.B.K., List, H., Harttig, H., Baader, F. Continuous glucose monitoring device. US076930 (2006).
269. Cheadle A, Goldberg HI, Hirsch IB, Hoath J, Mullen M, Ralston JD. Web-based collaborative care for type 2 Diabetes. Diabetes Care 2009; 32: 234-9.
270. O'Connor PJ, Crain AL, Rush WA, Sperl-Hillen JM, Gutenkauf JJ, Duncan JE. Impact of an electronic medical record on diabetes quality of care. Ann Fam Med 2005; 3(4):300-6.
271. Montori VM, Dinneen SF, Gorman CA, Zimmerman BR, Rizza RA, Bjornsen SS, et al. Translation Project Investigator Group. The impact of planned care and a diabetes electronic management system on community-based diabetes care: The Mayo Health System Diabetes Translation Project. Diabetes Care 2002; 25(11):1952-7.
272. O'Connor PJ. Electronic medical records and diabetes care improvement: Are we waiting for Godot? Diabetes Care Mar 2003; 26(3):942-3.
273. Bates DW, Teich J, Lee J, Seger D, Kuperman GJ, Ma'Luf M, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999; 6: 313-21.
274. Crosson JC, Ohman-Strickland PA, Hahn KA, DiCicco-Bloom B, Shaw E, Orzano AJ, et al. Electronic medical records and diabetes quality of care: Results from a sample of family medicine practices. Ann Fam Med 2007; 5(3):209-15.
275. Muthiah, S., Ilesh, K., Brian, K. Electronic medical record creation and retrieval system. US8311848 (2012).
276. Kevin, H., Tamara, S. Systems and methods for enabling telemedicine consultations and patient referrals. US60576 (2013).
277. Jonathan, R. Method and system for consulting remotely. US233894 (2004).
278. Stephen, J.B. Home health digital video recording system for remote health management. US281392 (2009).